Tradestie Institutional Equity Comparison Engine

DMAC vs GLUE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DMAC Overall Edge

DMAC Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while GLUE counters with relative strength in Valuation. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus GLUE at 10.0x Forward P/E and -214.5% operating margin (+325.8% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against GLUE sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner GLUE
DMAC N/M vs GLUE 10.0x Fwd P/E
Growth & Margin Winner DMAC
Op Margin 0.0% vs -214.5% ยท YoY +0.0% vs +325.8%
Momentum & Technical Winner DMAC
1Y +55.3% vs -36.4% ยท 52W Pos 55% vs 1%
Options & Structure Winner DMAC
SURGE (14th %ile IV) vs BREAKDOWN (16th %ile IV)
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
GLUE NASDAQ
Monte Rosa Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.11
-2.77% 1D
Market Cap $795.5M
1M Return -6.47%
1Y Return -36.38%
Forward P/E 10.0x
Unified AI Score
43.5 / 100 HOLD
Tech 29.0 Fund 52.0 Flow 70.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DMAC +55.26% GLUE -36.38% Spread: +91.64 pp (DMAC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period DMAC Revenue GLUE Revenue DMAC Op. Margin GLUE Op. Margin Margin Edge
FY2018 $0M N/A -1352.2% N/A DMAC
FY2024 N/A $80M N/A -107.3% GLUE
FY2025 N/A $120M N/A -43.8% GLUE

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DMAC (4) vs GLUE (6)
Institutional Metric DMAC GLUE Criterion Row Winner
Market Capitalization Scale $503.1M $795.5M Larger Scale GLUE
Trailing P/E Ratio Valuation N/M 10.0x Lower Multiple GLUE
Forward P/E Ratio Valuation N/M 10.0x Lower Multiple GLUE
Revenue Growth (YoY) Growth +0.0% +325.8% Higher Growth GLUE
Operating Margin (TTM) Profitability 0.0% -214.5% Higher Margin DMAC
Net Profit Margin Profitability 0.0% -186.2% Higher Margin DMAC
Return on Equity (ROE) Capital Efficiency -114.6% -35.3% Higher ROE GLUE
52-Week Range Position Momentum 55% ($5โ€“$11) 1% ($9โ€“$26) Stronger Trend DMAC
Beta / 30D Volatility Risk Regime 1.74ฮฒ ยท 98% Vol 0.94ฮฒ ยท 53% Vol Lower Realized Risk GLUE
Unified Institutional Score Composite Signal 46.3 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite DMAC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DMAC vs GLUE Buy Guide
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
GLUE BREAKDOWN
85d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live GLUE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DMAC nor GLUE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.